BioNTech SE (BNTX), a leading producer of COVID-19 vaccines, saw its stock plummet 5.2% in the pre-market trading session on Friday, November 15, 2024. This sharp decline came after President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services (HHS).
Kennedy, known for his vocal criticism of childhood vaccinations and federal health agencies, has raised concerns among investors about the potential impact on the vaccine industry. His appointment as the head of HHS has sparked fears of reduced public trust in vaccines, lower vaccination rates, and a potential resurgence of preventable diseases.
Trump's comments that he would allow Kennedy to "go wild" on health issues have further fueled uncertainty surrounding the future direction of vaccine policies and regulations under the new administration. Investors are wary of the potential negative effects on vaccine demand, sales, and the overall business environment for companies like BioNTech.